Quarterly Data Lifecycle Reviews and Compliance Reporting

The contract requires quarterly reviews to ensure data integrity, identify and remove obsolete analyses in accordance with standard operating procedures, and maintain full compliance with FDA data retention requirements. These activities are critical for upholding regulatory standards and ensuring that all retained data remains accurate, relevant, and legally defensible. Performance must align with established protocols to prevent inconsistencies or compliance gaps that could impact FDA oversight or audit outcomes. The work is performed at a designated location in Silver Spring, Maryland, under a subcontract arrangement issued by the FDA Negotiated Contracts Branch within the Department of Health and Human Services. The solicitation was posted on July 17, 2026, with a response deadline of July 30, 2026, and falls under NAICS code 541618, indicating classification as other scientific and technical consulting services. The contract does not include set-aside provisions, and no specific point of contact is listed for inquiries. Participation is contingent on successful submission prior to the noted deadline and adherence to the outlined compliance obligations.